

## Press Release

Saluggia, January the 20<sup>th</sup>, 2011

## DAILY REPORT ON THE TREASURY SHARES BUY-BACK PLAN OF DIASORIN SPA

With reference to the treasury shares buy-back plan, DiaSorin Spa informs to have purchased, on January 20<sup>th</sup>, 2011 n. 37,900 of treasury shares at an average unit price of Euro 33.4801 per share, for a total equivalent value of Euro 1,268,895.

Pursuant to the purchases executed as of today, DiaSorin Spa holds a total amount of n. 103,900 of treasury shares, corresponding to 0.186% of its shares capital.

The Chief Executive Officer

## About DiaSorin

DiaSorin S.p.A., an international player in the market for in vitro diagnostics, develops, produces and markets reagent kits for clinical laboratory diagnostics. The DiaSorin Group is comprised of 23 companies based in Europe, North, Central and South America, Africa and Asia. It has about 1,500 employees, including more than 110 research and development specialists, and operates six manufacturing and research facilities in Saluggia (Vercelli, Italy), Dietzenbach (Germany), Stillwater (USA), Dublin (Ireland), Dartford (UK) and Johannesburg (SA). The last two were part of the Murex business operations, recently acquired from the Abbott Group. Thanks to its direct sales organization and an international network of over 80 independent distributors, the Group is present in more than 60 countries, offering a broad array of high quality products that includes comprehensive lines for each of the clinical segments in which the Group operates: infectious and viral diseases, management of bone and calcium related diseases, thyroid pathologies, oncology and fertility testing.

For additional information, please visit our website: www.DiaSorin.it

Contacts:

Investor Relations Director Laura Villa DiaSorin S.p.A. laura.villa@DiaSorin.it +39 02 9647 4567 +39 348 15 11 542 Press Office Carolina Mailander c.mailander@mailander.it +39 335 655 56 51 Bruno Caprioli <u>caprioli@mailander.it</u> +39 335 590 14 02